Research ExplorerPublicationsTP53 and Prognosis in mCRPC Survival: Biology or Coincidence...

TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?

Standard

TP53 and Prognosis in mCRPC Survival: Biology or Coincidence? / Rebello, Richard J; Oing, Christoph; Gillessen, Silke; Bristow, Robert G.

In: CLIN CANCER RES, Vol. 25, No. 6, 15.03.2019, p. 1699-1701.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rebello, RJ, Oing, C, Gillessen, S & Bristow, RG 2019, 'TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?', CLIN CANCER RES, vol. 25, no. 6, pp. 1699-1701. https://doi.org/10.1158/1078-0432.CCR-18-3401

APA

Rebello, R. J., Oing, C., Gillessen, S., & Bristow, R. G. (2019). TP53 and Prognosis in mCRPC Survival: Biology or Coincidence? CLIN CANCER RES, 25(6), 1699-1701. https://doi.org/10.1158/1078-0432.CCR-18-3401

Vancouver

Rebello RJ, Oing C, Gillessen S, Bristow RG. TP53 and Prognosis in mCRPC Survival: Biology or Coincidence? CLIN CANCER RES. 2019 Mar 15;25(6):1699-1701. https://doi.org/10.1158/1078-0432.CCR-18-3401

Bibtex

@article{be934ad9854b451ebc604354031c4ad6,
title = "TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?",
abstract = "Cell-free circulating tumor DNA (ctDNA) or circulating tumor cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supersedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.See related article by De Laere et al., p. 1766.",
author = "Rebello, {Richard J} and Christoph Oing and Silke Gillessen and Bristow, {Robert G}",
note = "{\textcopyright}2019 American Association for Cancer Research.",
year = "2019",
month = mar,
day = "15",
doi = "10.1158/1078-0432.CCR-18-3401",
language = "English",
volume = "25",
pages = "1699--1701",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?

AU - Rebello, Richard J

AU - Oing, Christoph

AU - Gillessen, Silke

AU - Bristow, Robert G

N1 - ©2019 American Association for Cancer Research.

PY - 2019/3/15

Y1 - 2019/3/15

N2 - Cell-free circulating tumor DNA (ctDNA) or circulating tumor cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supersedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.See related article by De Laere et al., p. 1766.

AB - Cell-free circulating tumor DNA (ctDNA) or circulating tumor cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supersedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.See related article by De Laere et al., p. 1766.

U2 - 10.1158/1078-0432.CCR-18-3401

DO - 10.1158/1078-0432.CCR-18-3401

M3 - SCORING: Journal article

C2 - 30610102

VL - 25

SP - 1699

EP - 1701

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 6

ER -